| 标题 |
A Phase 1 Study of Plamotamab, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma: Recommended Dose Safety/Efficacy Update and Escalation Exposure-Response Analysis |
| 网址 | |
| DOI | |
| 其它 |
期刊:Blood 作者:Krish Patel; Peter A. Riedell; Hervé Tilly; Sairah Ahmed; Jean-Marie Michot; et al 出版日期:2022-11-29 |
| 求助人 | |
| 下载 |
PDF的下载单位、IP信息已删除
(2025-6-4)